Fatty Acids and Fat Malabsorption Publications

Resources

Learn more about the benefits of RELiZORB from David Clay Evans, MD, FACS, Jeanette Hasse, PhD, RD, LD, FADA, CNSC, and Beth Lyman, MSN, RN, FASPEN

The Challenges of Addressing Fat Malabsorption in Enterally Fed Patients (REL 19-307)

Publications

The use of RELiZORB is supported by the Consensus Statement, recently published in the Journal of Cystic Fibrosis.

Please consult the following referenced publications for more information on fatty acids and fat malabsorption.

Consensus Statement: Journal of Cystic Fibrosis

Schwarzenberg SJ, Borowitz D, 20 gastroenterologists, 23 CF physicians, 17 CF dietitians, and 1 PharmD. Challenging barriers to an option for improved provision of enteral nutrition. J Cyst Fibros. 2019;18(4):447-449.

Synopsis: The consensus statement characterizes RELiZORB as a “physiologically superior product,” with “proven success in a real-world setting,” which “can produce measurable, clinically relevant benefits.” The statement further observed that, “despite its effectiveness and intuitive sense, RELiZORB is frequently unavailable to patients due to the vicissitudes of insurance approvals in the US.” This lack of access prompted the authors to develop an independently prepared consensus statement to highlight these patient challenges.

Read the Latest Published Study on Longer Term Use of RELiZORB

Stevens J, Wyatt C, Brown P, Patel D, Grujic D, Freedman SD. Absorption and Safety with Sustained Use of RELiZORB Evaluation (ASSURE) study in patients with cystic fibrosis receiving enteral feeding. J Pediatr Gastroenterol Nutr. 2018;67(4):527-532.

Additional RELiZORB Studies and Articles

Freedman S, Orenstein D, Black P, et al. Increased fat absorption from enteral formula through an in-line digestive cartridge in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2017;65(1):97-101.

Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56(8):365-379.

Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother. 2006;60(9):502-507.

Donaldson J, Fed’kiv O, Pawlowska M, et al. The effectiveness of enzymatic replacement therapy measured by turbidimetry and the lipaemic index in exocrine pancreatic insufficient young, growing pigs, fed a high-fat diet. Adv Med Sci. 2009;54(1):7-13.

Jang YD, Lindemann MD, Monegue HJ, Stuart RL. The effects of fat-soluble vitamin administration on plasma vitamin status of nursing pigs differ when provided by oral administration or injection. Asian-Australas J Anim Sci. 2014;27(5):674-682.

Peretti N, Marcil V, Drouin E, Levy E. Mechanisms of lipid malabsorption in cystic fibrosis: the impact of essential fatty acids deficiency. Nutr Metab (Lond). 2005;2(1):11.

Wouthuyzen-Bakker M, Bodewes FAJA, Verkade HJ. Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. J Cyst Fibros. 2011;10(3):150-158.

For more information on how to order RELiZORB, contact RELiZORB Support Services at 1-844-632-9271.